Proteon Therapeutics, based in Waltham, Mass., announced that its PATENCY-2 Phase III clinical trial of vonapanitase in chronic kidney disease (CKD) failed to meet its co-primary endpoints. Vonapanitase was being evaluated in patients with Kidney disease (CKD) undergoing the creation of a radiocephalic…